OncoSil Receives FDA Approval for Distal Cholangiocarcinoma

Summary by 6ix AI

OncoSil Medical Ltd has announced that the U.S. FDA has granted Humanitarian Device Exemption approval for the OncoSil™ device, intended for the treatment of distal cholangiocarcinoma, a rare bile duct cancer. This approval marks a significant milestone for the company, allowing it to commence its U.S. commercialization strategy and market launch. The OncoSil™ device is the first FDA-approved Class III device for this indication, providing a new treatment option for patients with limited alternatives. OncoSil Medical plans to target leading academic cancer centers and expects to launch the device in the U.S. during the second half of the fiscal year.

Written by 6ix AI from the company’s filing. How 6ix writes summaries